重组白细胞介素2在已确诊巨细胞病毒感染免疫治疗中的体内应用。
In vivo application of recombinant interleukin 2 in the immunotherapy of established cytomegalovirus infection.
作者信息
Reddehase M J, Mutter W, Koszinowski U H
出版信息
J Exp Med. 1987 Mar 1;165(3):650-6. doi: 10.1084/jem.165.3.650.
Abstract
We have shown in a murine model system for cytomegalovirus (CMV) disease in the immunocompromised host that in vivo application of recombinant human IL-2 (rhIL-2) can enhance the antiviral effect of a limited number of CD8+T lymphocytes, not only in prophylaxis, but also in therapy, when virus has already colonized host tissues. The observed net effect of IL-2 was consistent with the assumption of daily effector population doublings. The prospects for IL-2-supported immunotherapy of established CMV infection depend upon the tissues involved in disease. It appears that the prospects for controlling established CMV adrenalitis are less promising than for a therapy of interstitial CMV pneumonia.
摘要
我们已经在免疫功能低下宿主的巨细胞病毒（CMV）病小鼠模型系统中表明，在体内应用重组人白细胞介素-2（rhIL-2）不仅在预防方面，而且在病毒已经定植于宿主组织时的治疗方面，都可以增强有限数量的CD8 + T淋巴细胞的抗病毒作用。观察到的IL-2的净效应与每日效应细胞群体倍增的假设一致。IL-2支持的已确诊CMV感染免疫疗法的前景取决于疾病所涉及的组织。看来，控制已确诊的CMV肾上腺炎的前景不如间质性CMV肺炎的治疗前景乐观。
相似文献
1
In vivo application of recombinant interleukin 2 in the immunotherapy of established cytomegalovirus infection.重组白细胞介素2在已确诊巨细胞病毒感染免疫治疗中的体内应用。
J Exp Med. 1987 Mar 1;165(3):650-6. doi: 10.1084/jem.165.3.650.
2
Adoptive immunotherapy of murine cytomegalovirus adrenalitis in the immunocompromised host: CD4-helper-independent antiviral function of CD8-positive memory T lymphocytes derived from latently infected donors.免疫功能低下宿主中鼠巨细胞病毒肾上腺炎的过继免疫疗法：源自潜伏感染供体的CD8阳性记忆T淋巴细胞的CD4辅助非依赖性抗病毒功能
J Virol. 1988 Mar;62(3):1061-5. doi: 10.1128/JVI.62.3.1061-1065.1988.
3
Refining human T-cell immunotherapy of cytomegalovirus disease: a mouse model with 'humanized' antigen presentation as a new preclinical study tool.精制人类 T 细胞免疫疗法治疗巨细胞病毒病：一种具有“人源化”抗原呈递的小鼠模型，作为新的临床前研究工具。
Med Microbiol Immunol. 2016 Dec;205(6):549-561. doi: 10.1007/s00430-016-0471-0. Epub 2016 Aug 18.
4
Failure in generating hemopoietic stem cells is the primary cause of death from cytomegalovirus disease in the immunocompromised host.无法生成造血干细胞是免疫功能低下宿主因巨细胞病毒病死亡的主要原因。
J Exp Med. 1988 May 1;167(5):1645-58. doi: 10.1084/jem.167.5.1645.
5
Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus.巨细胞病毒特异性细胞因子诱导的杀伤细胞：同时靶向白血病和巨细胞病毒
Cytotherapy. 2015 Aug;17(8):1139-51. doi: 10.1016/j.jcyt.2015.04.011. Epub 2015 Jun 10.
6
Adjuvant immunotherapy of established murine renal cancer by interleukin 2-stimulated cytotoxic lymphocytes.白细胞介素2刺激的细胞毒性淋巴细胞对已建立的小鼠肾癌进行辅助免疫治疗。
Cancer Res. 1986 Jul;46(7):3358-63.
7
8
Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.采用病毒特异性T细胞系对异基因干细胞移植后的早期巨细胞病毒感染进行过继性细胞治疗。
Lancet. 2003 Oct 25;362(9393):1375-7. doi: 10.1016/S0140-6736(03)14634-X.
9
10
Pathogenesis of cytomegalovirus pneumonia in immunocompromised hosts.免疫功能低下宿主巨细胞病毒肺炎的发病机制。
Semin Respir Infect. 1995 Dec;10(4):199-208.
引用本文的文献
1
Therapeutic Vaccination of Hematopoietic Cell Transplantation Recipients Improves Protective CD8 T-Cell Immunotherapy of Cytomegalovirus Infection.造血干细胞移植受者的治疗性疫苗接种可改善巨细胞病毒感染的保护性 CD8 T 细胞免疫治疗。
Front Immunol. 2021 Aug 19;12:694588. doi: 10.3389/fimmu.2021.694588. eCollection 2021.
2
Consequence of Histoincompatibility beyond GvH-Reaction in Cytomegalovirus Disease Associated with Allogeneic Hematopoietic Cell Transplantation: Change of Paradigm.同种异体造血细胞移植后与巨细胞病毒病相关的组织相容性不合的后果：观念转变。
Viruses. 2021 Aug 3;13(8):1530. doi: 10.3390/v13081530.
3
Immunodominant Cytomegalovirus Epitopes Suppress Subdominant Epitopes in the Generation of High-Avidity CD8 T Cells.免疫显性巨细胞病毒表位在高亲和力CD8 T细胞生成过程中抑制亚显性表位。
Pathogens. 2021 Jul 29;10(8):956. doi: 10.3390/pathogens10080956.
4
Recombinant interleukin-2 stimulates lymphocyte recovery in patients with severe COVID-19.重组白细胞介素-2可促进重症新型冠状病毒肺炎患者淋巴细胞恢复。
Exp Ther Med. 2021 Mar;21(3):227. doi: 10.3892/etm.2021.9658. Epub 2021 Jan 18.
5
Cytomegalovirus-Associated Inhibition of Hematopoiesis Is Preventable by Cytoimmunotherapy With Antiviral CD8 T Cells.通过抗病毒CD8 T细胞的细胞免疫疗法可预防巨细胞病毒相关的造血抑制。
Front Cell Infect Microbiol. 2020 Apr 21;10:138. doi: 10.3389/fcimb.2020.00138. eCollection 2020.
6
Mutual Interference between Cytomegalovirus and Reconstitution of Protective Immunity after Hematopoietic Cell Transplantation.巨细胞病毒与造血细胞移植后保护性免疫重建之间的相互干扰
Front Immunol. 2016 Aug 4;7:294. doi: 10.3389/fimmu.2016.00294. eCollection 2016.
7
Refining human T-cell immunotherapy of cytomegalovirus disease: a mouse model with 'humanized' antigen presentation as a new preclinical study tool.精制人类 T 细胞免疫疗法治疗巨细胞病毒病：一种具有“人源化”抗原呈递的小鼠模型，作为新的临床前研究工具。
Med Microbiol Immunol. 2016 Dec;205(6):549-561. doi: 10.1007/s00430-016-0471-0. Epub 2016 Aug 18.
8
Expression of chicken interleukin-2 by a highly virulent strain of Newcastle disease virus leads to decreased systemic viral load but does not significantly affect mortality in chickens.高致病性新城疫病毒株表达鸡白细胞介素-2导致鸡全身病毒载量降低，但对鸡的死亡率没有显著影响。
Virol J. 2015 Aug 8;12:122. doi: 10.1186/s12985-015-0353-x.
9
Principles for studying in vivo attenuation of virus mutants: defining the role of the cytomegalovirus gH/gL/gO complex as a paradigm.研究病毒突变体体内减毒的原则：以巨细胞病毒gH/gL/gO复合体为例确定其作用
Med Microbiol Immunol. 2015 Jun;204(3):295-305. doi: 10.1007/s00430-015-0405-2. Epub 2015 Mar 18.
10
Impaired CD8(+) T cell immunity after allogeneic bone marrow transplantation leads to persistent and severe respiratory viral infection.异基因骨髓移植后CD8(+) T细胞免疫受损导致持续性严重呼吸道病毒感染。
Transpl Immunol. 2015 Jan;32(1):51-60. doi: 10.1016/j.trim.2014.10.005. Epub 2014 Nov 5.
本文引用的文献
1
Adrenal necrosis in the acquired immunodeficiency syndrome.获得性免疫缺陷综合征中的肾上腺坏死
Ann Intern Med. 1984 Feb;100(2):239-41. doi: 10.7326/0003-4819-100-2-239.
2
Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome.白细胞介素-2可增强获得性免疫缺陷综合征患者淋巴细胞中降低的自然杀伤细胞活性和巨细胞病毒特异性细胞毒性活性。
J Clin Invest. 1983 Jul;72(1):398-403. doi: 10.1172/jci110981.
3
Cytomegalovirus infection and specific cell-mediated immunity after marrow transplant.骨髓移植后的巨细胞病毒感染与特异性细胞介导免疫
J Infect Dis. 1980 Dec;142(6):816-24. doi: 10.1093/infdis/142.6.816.
4
Pathogenesis of murine cytomegalovirus infection in natural killer cell-depleted mice.自然杀伤细胞缺失小鼠中鼠巨细胞病毒感染的发病机制
J Virol. 1984 Oct;52(1):119-28. doi: 10.1128/JVI.52.1.119-128.1984.
5
Significance of herpesvirus immediate early gene expression in cellular immunity to cytomegalovirus infection.疱疹病毒立即早期基因表达在巨细胞病毒感染细胞免疫中的意义。
Nature. 1984;312(5992):369-71. doi: 10.1038/312369a0.
6
Pathogenesis of pulmonary cytomegalovirus infection in immunosuppressed mice.免疫抑制小鼠肺部巨细胞病毒感染的发病机制
J Infect Dis. 1974 Jun;129(6):677-89. doi: 10.1093/infdis/129.6.677.
7
Congenital cytomegalovirus infection: a fifteen year perspective.先天性巨细胞病毒感染：十五年的观察视角
J Infect Dis. 1971 May;123(5):555-61. doi: 10.1093/infdis/123.5.555.
8
The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.使用淋巴因子激活的杀伤细胞和重组白细胞介素-2进行癌症的过继性免疫治疗。
Springer Semin Immunopathol. 1986;9(1):51-71.
9
Potential uses of interleukin 2 in cancer therapy.白细胞介素2在癌症治疗中的潜在用途。
Immunobiology. 1986 Sep;172(3-5):365-82. doi: 10.1016/S0171-2985(86)80118-8.
10
Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer.癌症患者中使用白细胞介素2给药及活化细胞过继性免疫治疗的临床试验结果。
Immunobiology. 1986 Sep;172(3-5):420-37. doi: 10.1016/S0171-2985(86)80122-X.
Zotero 插件